+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Effect of the lipase inhibitor orlistat on the pharmacokinetics of four different antihypertensive drugs in healthy volunteers



Effect of the lipase inhibitor orlistat on the pharmacokinetics of four different antihypertensive drugs in healthy volunteers



European Journal of Clinical Pharmacology 51(1): 87-90



Objective: To study the influence of the lipase inhibitor orlistat on the pharmacokinetics of the ant hypertensive drugs atenolol, furosemide, captopril and nifedipine. Methods: Four open-label, crossover studies were performed on six to eight healthy male volunteers. Orlistat was given in doses of 50 mg 3 times daily mid-meal for 7 (nifedipine and captopril) or 8 days (atenolol and furosemide). The four antihypertensive drugs (atenolol 100-mg tablet, furosemide 40-mg tablet, captopril 50-mg tablet and nifedipine 20-mg slow-release tablet) were administered in single doses twice, once before and once together, with orlistat at the end of the orlistat treatment period. Results: The plasma concentration time profiles and the pharmacokinetic parameters estimated for these drugs were in the expected range, except for furosemide, whose bioavailability was lower than reported in the literature. This was probably due to the fact that furosemide was given during a meal. There were minor, but statistically significant, differences in one of the pharmacokinetic parameters of furosemide and nifedipine (no difference for captopril and atenolol) when these drugs were given alone and in combination with orlistat: the half-life of furosemide was slightly longer, the time to peak plasma concentrations of nifedipine was slightly longer. None of these are considered to be clinically significant changes. Conclusions: The lipase inhibitor orlistat given 50 mg 3 times daily does not alter the pharmacokinetics of atenolol, furosemide, nifedipine and captopril to a clinically significant extent.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 008549401

Download citation: RISBibTeXText

PMID: 8880057

DOI: 10.1007/s002280050165


Related references

Effects of orlistat, a lipase inhibitor, on the pharmacokinetics of three highly lipophilic drugs (amiodarone, fluoxetine, and simvastatin) in healthy volunteers. Journal of Clinical Pharmacology 43(4): 428-435, 2003

The Effect of Orlistat, an Inhibitor of Dietary Fat Absorption, on the Pharmacokinetics of -Carotene in Healthy Volunteers. The Journal of Clinical Pharmacology 36(2): 152-159, 1996

The effect of orlistat, an inhibitor of dietary fat absorption, on the pharmacokinetics of beta-carotene in healthy volunteers. Journal of Clinical Pharmacology 36(2): 152-159, 1996

The interaction of the lipase inhibitor orlistat with ethanol in healthy volunteers. European Journal of Clinical Pharmacology 54(9-10): 773-777, 1998

Review of limited systemic absorption of orlistat, a lipase inhibitor, in healthy human volunteers. Journal of Clinical Pharmacology 35(11): 1103-1108, 1995

The effect of orlistat on the pharmacokinetics of phenytoin in healthy volunteers. Journal of Clinical Pharmacology 36(7): 654-658, 1996

The effect of orlistat on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers. Journal of Clinical Pharmacology 36(7): 659-666, 1996

The effect of orlistat on the pharmacokinetics and pharmacodynamics of glyburide in healthy volunteers. Clinical Pharmacology and Therapeutics 53(2): 230, 1993

The effect of orlistat on the pharmacokinetics and pharmacodynamics of warfarin and on the absorption of vitamin K in healthy volunteers. Pharmaceutical Research (New York) 12(9 Suppl. ): S410, 1995

Effect of orlistat on the pharmacokinetics of repeated doses of sustained-release bezafibrate in healthy volunteers. Fundamental and Clinical Pharmacology 14(3): 246, 2000

The effect of the oral direct thrombin inhibitor ximelagatran on the pharmacokinetics of P450-metabolized drugs, in healthy male volunteers. Blood 98(11 Part 2): 89b, 2001

The influence of orlistat on the pharmacokinetics and pharmacodynamics of glyburide in healthy volunteers. Journal of Clinical Pharmacology 35(5): 521-525, 1995

The effect of orlistat, an inhibitor of dietary fat absorption, on the absorption of vitamins A and E in healthy volunteers. Journal of Clinical Pharmacology 36(7): 647-653, 1996

The influence of reduced dietary fat absorption induced by orlistat on the pharmacokinetics of digoxin in healthy volunteers. Journal of Clinical Pharmacology 35(8): 840-843, 1995

Fat malabsorption and gut transit in healthy subjects Studies with orlistat, a specific lipase inhibitor. Gastroenterology 112(4 Suppl. ): A719, 1997